Evolution of the Average Target: Cartesian Therapeutics, Inc.

Evolution of the Average Target - Cartesian Therapeutics, Inc.

Evolution of the Target Price: Cartesian Therapeutics, Inc.

Evolution of the Target Price - Cartesian Therapeutics, Inc.

Changes in Analyst Recommendations: Cartesian Therapeutics, Inc.

ca6084066ab321eed457608a.9zvz4daECUrbYqdA6gdpt2um5qKwNqgWSXWz4B90X3I.nW6su53JcCyUW8Ar039c5iDnvMj3Y-pVJQaGrnofBj29dsuLpNZ5Pu8b8g~1ddb1407c94e36734cea4df637eb31c6
21/10/25 Cartesian Therapeutics, Inc. Announces Departure of Chief Scientific Officer, Christopher Jewell, Ph.D., Effective November 14, 2025 CI
09/07/25 Wedbush Initiates Cartesian Therapeutics at Outperform With $38 Price Target MT
19/12/24 BTIG Research Initiates Coverage on Cartesian Therapeutics With Buy Rating, $42 Price Target MT
06/08/24 TD Cowen Starts Cartesian Therapeutics With Buy Rating MT
03/07/24 Canaccord Genuity Raises Price Target on Cartesian Therapeutics to $43 From $38, Maintains Buy Rating MT
03/07/24 HC Wainwright Adjusts Price Target on Cartesian Therapeutics to $49 From $54, Maintains Buy Rating MT
02/07/24 Oppenheimer Downgrades Cartesian Therapeutics to Market Perform From Outperform; Shares Tumble MT
04/06/24 Oppenheimer Initiates Cartesian Therapeutics With Outperform Rating, $50 Price Target MT
24/05/24 Mizuho Securities Starts Cartesian Therapeutics With Buy Rating MT
23/04/24 Leerink Partners Starts Cartesian Therapeutics With Outperform Rating, $39 Price Target MT
18/08/23 Mizuho Trims Price Target on Selecta Biosciences to $3 From $4, Maintains Buy Rating MT
18/08/23 Needham Adjusts Price Target on Selecta Biosciences to $4 From $5, Maintains Buy Rating MT
22/03/23 HC Wainwright Adjusts Price Target on Selecta Biosciences to $5 From $4, Maintains Buy Rating MT
22/03/23 Mizuho Securities Adjusts Selecta Biosciences Price Target to $4 From $5, Maintains Buy Rating MT
31/01/23 Canaccord Genuity Adjusts Selecta Biosciences Price Target to $9 From $10, Maintains Buy Rating MT
21/06/22 HC Wainwright Adjusts Price Target on Selecta Biosciences to $4 From $6, Reiterates Buy Rating MT
14/06/22 Needham Adjusts Price Target on Selecta Biosciences to $5 From $6, Reiterates Buy Rating MT
06/06/22 SVB Securities Initiates Selecta Biosciences at Outperform With $7 Price Target MT
15/06/21 Selecta Biosciences : BTIG Starts Selecta Biosciences at Buy With $10 Price Target MT
12/03/21 Selecta Biosciences : William Blair Upgrades Selecta Biosciences to Outperform from Market Perform MT
26/01/21 Selecta Biosciences : Mizuho Upgrades Selecta Biosciences to Buy From Neutral, Adjusts Price Target to $8 From $2.50 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+444.77%
+32.59%
+28.07%
+10.26%
+8.34%
+15.58%
+38.43%
+38.53%
+31.23%
+4.99%
Average +65.28%
Weighted average by Cap. +23.55%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
6.180USD
Average target price
33.67USD
Spread / Average Target
+444.77%
High Price Target
44.00USD
Spread / Highest target
+611.97%
Low Price Target
16.00USD
Spread / Lowest Target
+158.90%

Analyst Consensus Detail

Analyst consensus - Cartesian Therapeutics, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Cartesian Therapeutics, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cartesian Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. RNAC Stock
  4. Consensus Cartesian Therapeutics, Inc.